Abstract 102

نویسندگان
چکیده

برای دانلود باید عضویت طلایی داشته باشید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Abstract 102: Keap1/Nrf2 Dysfunction Impairs Wound Healing in Diabetes

RESULTS: In the wound bed, Keap1 siRNA treated mice decreased Keap1 gene expression (55.4 ± 22.9%; p=0.004) and protein expression (94 ± 0.42%; p=0.038) compared to controls. Downstream protein expression of Nrf2 increased (3.27 ± 1.63 fold; p=0.039). The expression of antioxidant genes, NQO-1 and MnSOD-1 increased (4.99 ± 0.1 fold; p=0.04 and 3.66 ± 0.2 fold; p=0.01, respectively). The express...

متن کامل

Npgrj_nchembio_760 95..102

Chronic myelogenous leukemia (CML) is a myeloproliferative disorder characterized at the molecular level by the expression of Bcr-abl, a 210-kDa fusion protein with deregulated tyrosine kinase activity. Encouraged by the clinical validation of Bcr-abl as the target for the treatment of CML by imatinib, we sought to identify pharmacological agents that could target this kinase by a distinct mech...

متن کامل

Tf-ilpr150008 96..102

Previous studies from this group have shown that limit size lipid-based systems – defined as the smallest achievable aggregates compatible with the packing properties of their molecular constituents – can be efficiently produced using rapid microfluidic mixing technique. In this work, it is shown that similar procedures can be employed for the production of homogeneously sized unilamellar vesic...

متن کامل

Pg 102-107

Great strides were made during the last century in the management of diabetes in pregnancy. Before the discovery of insulin in 1921 the outlook for the diabetic mother and her fetus was abysmal. With the advent of insulin, an emphasis on a team approach to care, improved methods of fetal surveillance, and a focus on metabolic normalisation brought about by intensive insulin regimens and home gl...

متن کامل

Dmd065615 102..114

N-Methyl-2-[3-((E)-2-pyridin-2-yl-vinyl)-1H-indazol-6-ylsulfanyl]benzamide (axitinib) is an oral inhibitor of vascular endothelial growth factor receptors 1–3, which is approved for the treatment of advanced renal cell cancer. Human [C]-labeled clinical studies indicate axitinib’s primary route of clearance is metabolism. The aims of the in vitro experiments presented herein were to identify an...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

ژورنال

عنوان ژورنال: Plastic and Reconstructive Surgery - Global Open

سال: 2020

ISSN: 2169-7574

DOI: 10.1097/01.gox.0000667464.80425.d8